Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tommysdad who wrote (1533)	9/2/2000 6:45:58 PM
From: Biomaven	Read Replies (2) of 52153

Here's a little more on the MLNM ACE2 discovery from an article in the Boston Globe: Even as investment analysts warned that the discovery might never lead to a drug, they hailed it as more evidence of Millennium's strong position in genomics. "It's only one example of many that Millennium can point to where they're succeeding at finding new drug targets," said Carolyn Pratt, biotechnology analyst in Needham & Co.'s Boston office. "They just keep doing this over and over again." Millennium scientists found ACE2 while sifting through 19,000 gene sequences found in biopsies of human hearts suffering from heart failure. The gene caught the scientists' attention, Breitbart said, because of its similarities to ACE. After more study, they realized it was a good potential target for new drugs because of its differences. "If it responded to the ACE inhibitors, we wouldn't pursue this project," Breitbart said. "It's exciting because it gives us another potential way to treat cardiovascular disease." Sounds like this turned up in some sort of differential expression analysis. I wonder if GLGC has had any similar discoveries? Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next